Principles of organ transplant

PRINCIPLES
INVOLVED IN ORGAN
TRANSPLANT
DR BASHIR YUNUS
SURGERY DEPT.
AKTH
19/1/15
1/19/2015bbinyunus2002@gmail.com 1

OUTLINE
O INTRODUCTION
O Definition of terms
O Transplant immunology
O Graft rejection
O PRINCIPLES
O Pre-operatives
O Intra-operatives
O Post-operative
O COMPLICATIONS
O RENAL TRANSPLATATION
O ETHICAL CONSIDERATIONS
O CONCLUSION
O REFERENCES

INTRODUCTION
DEFINITION OF TERMS
• An organ transplant is a surgical procedure in which a failing
organ is replaced by a functioning one from a donor with a
compatible tissue type.
• Autograft
• Allograft
• Isograft
• Xenograft
• Orthotopic graft
• Heterotopic graft
1/19/2015bbinyunus2002@gmail.com
3

INTRODUCTION
• TRANSPLANT IMMUNOLOGY
The immune system recognizes graft from someone else as foreign and
triggers response via immune cells or substances they produce -
cytokines and antibodies
• Responses are via; recognition, amplification and memory
• CELL;
• Lymphocytes; T-lymphocyte, B-lymphocyte, N-killer cells
• Antigen presenting cells(APC); macrophages, dendritic cells
• The Effector Cells; Neutrophils , macrophages and T-lymphocytes
• T-LYMPHOCYTES
• Mediator of cell mediated immunity
• They recognizes MHC antigen on transplant tissues
• Cytotoxic T-cells produces cytotoxic factors (perforins, granzymes)
implicated in transplant rejection
4

Cell-mediated immune response
Defend against intracellular pathogens/rejection
Active
Cytotoxic T cells
Memory
Cytotoxic T cells
Memory
Helper T cells
Antigen-
presenting cell
Antigen (2nd exposure)
Helper T cell
Engulfed by
Antigen (1st exposure)
Cytotoxic T cell
Key
Stimulates
Gives rise to
+
+
+
+
+ +
+
5

Cytotoxic T cell
Perforin
Granzymes
TCRCD8
Class I MHC
molecule
Target
cell
Peptide
antigen
Pore
Released cytotoxic T cell
Dying target cell
6

B-LYMPHOCYTES
• Mediators of humeral immunity by antibody production.
• There activation is aided by cytokine and the T-helper cells
• Clonal selection generates plasma secreting antibodies.
• There are 5 major classes of antibodies or immunoglobulin; IgG,
IgM, IgA, IgE and IgD the 1st 3 are involve in graft rejection
N-KILLER CELLS
• Cells of innate immunity, capable of killing foreign targets without
prior sensitisation
7

Key
Stimulates
Gives rise to
+
Memory
Helper T cells
Antigen-
presenting cell
Helper T cell
Engulfed by
Antigen (1st exposure)
+
+
+
+ +
+
Defend against extracellular pathogens/Transplant rejection
Memory
B cells
Antigen (2nd exposure)
Plasma cells
B cell
Secreted
antibodies
Humoral (antibody-mediated) immune response
8

• ANTIGEN PRESENTING CELLS(APC)
• They capture antigens and display to lymphocytes e.g.
Macrophages, dendritic cells and follicular dendritic cells.
• Dendritic cells; initiate T-cells response
• Macrophages; Initiate effector phase of cell mediated immunity
• Follicular dendritic cells; display antigens to B-lymphocytes in
humeral response.
• EFFECTOR CELLS
• They eliminate antigens by phagocytosis
• E.g neutrophils, macrophage and T-lymphocytes
9

APC
10

TRANSPLANT ANTIGENS
Human leucocytes antigen(HLA);
O a group of highly polymorphic cell surface
molecules
O They act as antigen recognition unit on T-
lymphocytes and are the major trigger for
graft rejection
O Types; class1 –A,B,C present in all
nucleated cells, class2 – HLA-
DR,DP,DQ present only on APC
O Class 2- HLA-DR are most important in
rejection
O CD8+ and CD4+ recognize class 1 and 2
receptors respectively

MHC;
O Major histocompatibility complex. They
are clusters of genes on the short arm of
chromosome 6 expressed on the cell
surface as HLA i.e. genes that encode
HLA.
ABO
O These blood group antigen are expressed
not only on red blood cells but by most cell
types as well.
O Incompatibility leads to hyperacute
rejection

GRAFT REJECTION;
Rejection of transplanted organs is a bigger
challenge than the technical expertise
required to perform the surgery. It results
mainly from HLA and ABO incompatibility.
O Hyperacute
O Acute
O Chronic

Hyperacute rejection
O Immediate graft destruction due to ABO
or preformed anti- HLA antibodies.
O Characterized by intravenous
thrombosis and interstitial hemorrhage.
O Risk factors are previous failed transplant
and blood transfusions
O Kidney transplant is vulnerable to
hyperacute rejection

Acute rejection
O Usually occurs during the first 6month
O May be cell mediated (T-cell), antibody
mediated or both
O Characterized by cellular infiltration of
the graft(cytotoxic, B- cells, NK cells and
macrophages )

CHRONIC REJECTION
O it occurs after 6month
O Most common cause of graft failure
O Antibodies play important role
O Non- immunological factors contribute to
the pathogenesis
O Characterized by myointimal
proliferation in graft arteries leading to
ischemia and fibrosis

PRINCIPLES
1. PRE-OPERATIVE
O Patient selection and Evaluation
O Counseling
O Informed consent
O optimization

PATIENT SELECTION AND EVALUATION
RECIPIENT
O Patient who met the indication for transplant –
ORGAN FAILURE
O Clinical evaluation; history and physical
examination to rule out other diseases and co-
morbidities
O Immunological evaluation
O Serology; HIV, Hepatitis, CMV, VDRL
O Tissue typing & cross matching
O Blood group
O Infection screening – septic work-up, mantoux
O Others ; FBC, clotting profile, FBS, ECG, U/Ecr,
tumour markers, stool microscopy

Patient selection
O DONOR
a) Cadaveric
O Individuals with severe brain injury
resulting in brain death-Brain death is
defined as “complete irreversible
cessation of all brain functions”.

Other criteria;
O Normothermic patient.
O No respiratory effort by the patient.
O The heart is still beating.
O No depressant drugs intake should be
there while evaluating the patient.
O Individual should not have any sepsis,
cancer (except brain tumour).
O Not a HIV or hepatitis individual.

b. Living donor;
a living donor should be healthy
Living unrelated donor or
Living related donor.
O Improved graft survival
O Less recipient morbidity
O Early function and easier to manage
O Avoidance long waiting time for transplant
O Less aggressive immunosuppressive regimen

O Contra-indications for living donor ;
O Mental disease
O Disease organ
O Morbidity and mortality risk
O ABO incompatibility
O Crossmatching incompatibility
O Transmissible disease

Evaluation; to assess for suitability
O CLINCAL; history of risk factors for infection,
malignancy in the past 5 years. Presence of
co-morbidities
O ABO typing.
O Serology tests.
O Infection and malignant screening
O CT-Angiogram;
O Intravenous urography.
O HLA typing.

FACTORS DETERMING ORGAN
FUNCTION AFTER TRANSPLANT
DONOR CHARACTERISTICS
O ■ Extremes of age
O ■ Presence of pre-existing disease in the transplanted
organ
O ■ Haemodynamic and metabolic instability
PROCUREMENT-RELATED FACTORS
O ■ Warm ischaemic time
O ■ Type of preservation solution
O ■ Cold ischaemic time
RECIPIENT-RELATED FACTORS
O ■ Technical factors relating to implantation
O ■ Haemodynamic and metabolic stability
O ■ Immunological factors
O ■ Presence of drugs that impair transplant function

Tissue typing
O The tissue typing laboratory carries out 3
tasks
O To determine the HLA type of blood for
both donor and recipient by PCR.
O Lymphocyte crosshatching to exclude
circulating antibodies in recipient against
HLA expressed by donor.
O HLA antibody screening and specificity
in recipient before and after transplant to
guide immunosuppressive therapy

O Positive cross matching;
O Recipient antibodies attacks donor’s.
O Not suitable for transplant
O Negative cross matching;
O Recipient antibodies donot attack donor
O Suitable for transplant
O Methods;
O Microcytotoxic assay, mixed lymphocytes,
flow cytometory, DNA analysis.

PRE-OPERATIVE
O Patient selection and Evaluation
O Counseling
O Informed consent
O optimization

COUNSELING
O May involve professional counselors/
psychotherapist
O Aimed at preventing / minimizing possible
complication
O Need for adherance to post-op maintenance
medications
O Regular follow-up thorough evaluation
O life style modification; smoking, alcohol,
sedentary life style, junks, excessive salt
ingestion.

INFORMED CONSENT
O Living Donor ;
O Education
O Willingly not for any financial reason or
under duress
O Most undergo extensive screening –
medical phycological
O Involve family
O Surgery and anaesthetic complications
complications outline to patients

O DECEASE DONOR
O Some Factors influencing refusal to consent by
relatives;
O non-acceptance of brain death.
O Superstitions relating to being reborn with a
missing organ
O A delay in funeral
O Lack of consensus within family members
O Fear of social criticism
O Dissatisfaction with the hospital staff
O Religious believes

INFORMED CONSENT
O RECIPIENT
O Nature of disease and the need for
transplant
O Outcome and complications
O Need for compliance to
immunosuppressive therapy
O Other available options

OPTIMIZATION OF RECIPIENT
Correction of derangements, getting patient ready for
surgery
O Correction of anaemia
O Uremia
O Dehydration
O Treatment of infection
O Treatment of malaria
O Deworming of patient
O Central line
O Urethral catheter
O Loading dose immunosuppression 12hr pre-op
O Prophylactic antibiotics

PRINCIPLES
INTRA-OPERATIVE
Organ procurement and preservation
Living donors
a. Strict asepsis and hemostasis
b. Adequate exposure
c. Control of the vessels above and below
the organs to be removed is done- cross
clamping
d. Removal of the organ

34

g. Organ packaging

Deceased donor

NONHEART-BEATING KIDNEY DONATION
Initiation of preservation in situ- for
DCD donors- donation after circulatory
death donors

h. Transplantation/vascular
reconstruction
Warm ischemic time ; time an organ
remains at body temperature between which
the blood supply is cut off before cold
perfusion. (within 30min)
Cold ischemic time ; the time between the
chilling of the organ, after blood supply has
been cut off and the time it is warmed by
reconnection 1/19/2015bbinyunus2002@gmail.com 38

Maximum and optimal cold storage times
(approximate)a
O Organ Optimal (hours ) Safe
maximum(hours)
O Kidney < 24 48
O Liver < 12 24
O Pancreas < 10 24
O Small intestine < 4 8
O Heart < 3 6
O Lung < 3 8
Assuming zero warm ischaemic time and organs
obtained from a non-marginal

PRINCIPLES
O Post-operative
O Post-operative assessment
O Clinical –vital signs; fever, tarchychadia, hypertension, pain at
site of transplant, pedal oedema (compession of external iliac
vein), decrease urine volume- features of hyperacute rejection
O Investigations ;
 U/Ecr
 USS- increase in size, pelvicalyceal dilation
 Biopsy; mononuclear infiltrates, fibrinoid necrosis, interstitial
haemorrhage.
 Others
O Maintenance immunosuppression
O DVT prophylaxis
O Treatment of infection
O Regular follow up

IMMUNOSUPPRESSION
O The principles are the same for type of
organ transplant; maximize graft
protection and minimize side effect.
O The agents used to prevent rejection act
predominantly on T cells.
O The need for immunosuppression is
highest in the first 3 month but indefinite
treatment is needed
O It increase the risk of infection and
malignancy.

AGENT MODE OF ACTION SIDE FFECT
CALCINEURINE
INHIBITORS
Cyclosporine
tacrolimus
Block IL-2 gene
transcription
Nephrotoxicity,
hypertension,
dyslipidaemia, hirsutism,
gingival hyperplasia,
neurotoxicity and diabetes
AZATHIOPRINE Prevents lymphocyte
proliferation
Leucopenia,
thrombocytopenia,
hepatotoxicity,
gastrointestinal
symptoms
MYCOPHENOLIC ACID
DERIVATIVES eg MMF –
mycofenolate mofetil
Prevents lymphocyte
proliferation
Leucopenia,
thrombocytopenia,
gastrointestinal symptoms
CORTICOSTEROIDS Widespread anti-
inflammatory
effects
Hypertension,
dyslipidaemia, diabetes,
osteoporosis, avascular
necrosis,
cushingoid appearance
mTOR-inhibitors
Sirolimus, everolimus
Blocks IL-2 receptor signal
transduction
Thrombocytopenia,
dyslipidaemia,

AGENT MODE OF ACTION SIDE EFFECT
ANTIBODY THERAPIES
a. OKT3 monoclonal
antibody
b. Anti-CD25 monoclonal
antibody
c. Polyclonal antibody
[antilymphocyte
globulin (ALG) or anti-
lymphocyte serum (ALS)]
Depletion and blockade of
T
Cells
Targets activated T cells
Depletion and blockade of
lymphocytes
a. Cytokine release
syndrome, pulmonary
oedema, leucopenia
b. None described
c. Leucopenia,
thrombocytopenia

REGIMENS
O Immunosuppressive agents are given as
O Induction; early post-op period
O Maintanance ; given for life
O Rescue agents ; to reverse acute rejection
O Induction regimen (most currently used )
 CNI + anti CD 25 monoclonal antibody
 Triple therapy ; CNI, antiproliferative agent
(MMF) and steroids
 Dual therapy ; CNI + MMF or steroids
 Polyclonal antibody (ALG/ALS)

O Maintenance ;
O mTOR- inhibitors (esp in kidney transplant
because they provide a noo-nephrotoxic
alternative to CNI)
O Multidrug therapy ; steroids, antiproliferatives,
CNIs, lymphocytes sequestration –FTY720
O Acute rejection;
O Polyclonal antibody combine with induction
regimen- quadruple therapy.

COMPLICATIONS OF
IMMUNOSUPPRESSION
O INFECTIONS; high risk of opportunistic
infections
O Bacterial; common during first month after
transplantation / before recovery from
surgery
 Community acquired infections
 Wound infection
 UTI (catheter related)
 Tuberculosis

O Viral ; highest in the first six month
 CMV infection; may presents as
pnuemonia, gastrointestinal disease,
hepatitis, retinitis, encephalitis
 Herpes simplex virus (HSV) ;
mucocuteneous lesions sometimes around
the genitalia
 BK-virus; graft dysfunction
 Herpes zoster infection; chicken pox
O Fungal ; pneumocystic jiroveci(carinii),
candidiasis, aspergillosis
O Parasitic; strongiloides, leimaniasis,
toxoplasmosis

O MALIGNANCY
 Post transplant lymphoprolipherative
disease (PTLPD); seen 1-3% of kidney
transplant with 50% mortality
 Squamous cell ca of the skin
 Basal cell ca and malignant melanoma are
higher in transplant patient than the genral
population
 50% of transplant patient would develop skin
malignancy in 20years
 Kaposi sarcoma; 300 fold increased risk

KIDNEY TRANSPLANT
O Indications
O End-stage renal disease
Causes
O glomerulonephritis;
O diabetic nephropathy;
O hypertensive nephrosclerosis;
O renal vascular disease;
O polycystic disease;
O pyelonephritis;
O obstructive uropathy;
O systemic lupus erythematosus;
O analgesic nephropathy;
O metabolic disease (oxalosis, amyloid).

Exclusion criteria for living donor
O

OPERATIVES
O DONOR NEPHRECTOMY
O DONOR BENCH SURGERY
O TRANSPLANTATION

O Donor Nephrectomy
O Open or laparoscopic
O Open donor nephrectomy is the gold standard
O Open donor nephrectomy is via the 12th rib
incision, and in fat patient 10th rib or
hypogastrium
O Extraperitoneal : avoid devascularizing ureter,
sharp dissection, avoid diathermy near vessels
O Renal vasculature dissect flush to IVC/Aorta
O Ligate lumbar veins posteriorly ± gonadal vein

Donor Kidney Bench Surgery
O The kidney is perfused with ice-cold
preservative
O Iced saline is mashed into a slush and
kidney immersed
O Extra veins ligated, accessory artery(ies)
anastamosed together
O Kidney now ready for transplanting

THE TRANSPLANT
O Right donor kidney to left recipient site
and vice versa
O Gibson’s incision; Curvilinear incision 2
cm above the inguinal ligament, from
midline to just above the anterior Sup.
Iliac Spine
O End to side venous anastamosis 5/0
prolene
O End to end arterial anastamosis 5/0
prolene
O Implant ureter to bladder 1/19/2015bbinyunus2002@gmail.com 55

COMPLICATIONS
O TECHNICAL
O Vascular hemorrhage; Vascular thrombosis 10-
20%, within 2-3 days→ technical, 2/12→rejection,
most are lost: ↓urine output, ↑creat
O Urological ; infection, fistula, obstruction
O Wound infection
O RENAL
O Acute tubula necrosis
O Cortical necrosis
O Lymphocele
O Graft rupture
O Recurrent glomerulo-nephritis

Outcome
O Patient survival after deceased donor
renal transplantation is >90% at 1 year
and > 80% at 5 years.
O Graft survival is around90% at 1 year and
75% at 5 years. Graft survival after a
second transplant is only marginally worse
than after a first graft.
O After living-related kidney transplantation,
overall graft survival is around 95% at 1
year and 85% at 5 years.

ETHICAL CONSIDERATION
INTERNATIONAL PERSPECTIVES ON
THE ETHICS AND REGULATION OF
HUMAN CELL AND TISSUE
TRANSPLANTATION
O Consent for removal of human cells and
tissues
O Confidentiality of donor data
O Unpaid donation
O Fair procurement of cells and tissues
O Stewardship for donated cells and tissues
O Quality and safety of HC/HT procurement and
processing
O Fair distribution of processed cells and tissues
O Consent for HC/HT transplantation 1/19/2015bbinyunus2002@gmail.com 59

Future trend
O Genetic engineering –cloning
O Newer specific immuno-suppresive
therapy

CONCLUSION
O Organ transplant is a successive
therapeutic option for treatment of end-
stage organ disease. Success depends
on improved surgical technique,
immunosuppression, organ
preservation and follow-up .

REFERENCES
O Bailey and Love’s “Short Practice of Surgery”
26th edition CRC press Taylor and Francis group.
2013
O E.A Badoe et al, “Principles and Practice of
surgery including pathology in the tropics” 4th
edition, Assembly of God Literature Center ltd,
2009
O M.A.R Al-Fallouji; “Postgraduate Surgery the
candidate guide”. 2nd Edition. Rced Educational
and Professional Pub. Ltd 1998
O Sabiston texbook of surgery. 18th edition.2007
O Andrew C et al “Operative urology at the cleveland
clinic” 2nd edition. 2006.

Principles of organ transplant

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (20)

Ähnlich wie Principles of organ transplant

Ähnlich wie Principles of organ transplant (20)

Mehr von Bashir BnYunus

Mehr von Bashir BnYunus (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Principles of organ transplant